chronic disseminated intravascular coagulation
Conditions
Interventions
Administration of rivaroxaban for chronuc DIC (10mg, once a day for 5 years)
Sponsors
Hidesaku Asakura, Kanazawa University School of Medicine.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with DIC, diagnosed with diagnostic criteria of DIC of Japanese Ministry of Health and Welfare. 2. Patients over 20 years old at the time of obtaining informed consent. 3. Patients whose written consent has been obtained from the the patients or legal representative
Exclusion criteria
Exclusion criteria: 1. Patients with a history or serious drug allergy. 2. Patients with severe renal failure. 3. The patient, who are at risk of promoting the bleeding by administration of rivaroxaban. 4. The patients, who are presumed to die soon even though DIC is improvred. 5. The patients, who are pregnant, likely to be pregnant or breast-feeding. 6. The patients, who are not judged suitable for study patients by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety of rivaroxaban in treatment for chronic DIC (bleeding and thrombotic symptoms are estimated at 2w, 1M, 3M, 6M, 12M, 2y, 3y, 4y and 5y) | — |
Secondary
| Measure | Time frame |
|---|---|
| effectiveness of rivaroxaban in treatment for chronic DIC | — |
Countries
Japan
Contacts
Public ContactHidesaku Asakura
Kanazawa University School of Medicine. Department of Internal Medicine (III)
Outcome results
None listed